PCSK9 and coronary artery disorder: The ESC guideline target for LDL-C changed from 2.5 mmol/L to 1.8 mmol/L after the completion of inclusion of patients in the RESPONSE trial.15 This change increases the need for new initiatives to reach LDL-C targets in patients with CHD, as it is shown that only a minority of patients reach these stricter targets.4 The specific role of NCC in this process needs further evaluation, especially with the upcoming availability of new pharmacological strategies, such as PCSK9-inhibitors.